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Abstract
In two-arm randomized controlled trials (RCTs) with baseline covariates that are
prognostic for the outcome of interest, baseline covariate adjustment can improve
precision of the estimated marginal treatment effect and increase statistical power,
for a fixed sample size. Many adjusted estimators for the marginal treatment effect
have been proposed for a variety of outcomes and the statistical properties of these
estimators have been demonstrated via simulation studies in large sample RCTs.
However, there is little guidance on the use of these adjusted estimators in RCTs
with small sample sizes.
Motivated by an ongoing RCT (TREAT Parents trial), we conduct a simulation
study to evaluate the statistical behavior of adjusted estimators for both time to
event and binary outcomes in small sample RCTs, using the adjusted estimator for
the marginal log hazard ratio proposed by Lu an Tsiatis (2008) for the primary time
to event endpoint and several adjusted estimators of the marginal risk difference
for the secondary binary endpoint. We considered hypothetical trials with small
effective sample sizes, i.e. the expected number of events, ranging from 20 to 100. We
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also considered 3 scenarios with varying degrees of correlation between the baseline
covariates and the primary and secondary outcomes, including the scenario where
the baseline covariates are independent of the outcomes. The hypothetical trials were
generated in ways that mimic the observed characteristics within TREAT Parents
trial.
Our simulation results demonstrated that precision gains in the estimated marginal
treatment effect can be achieved when adjusting for baseline variables that are cor-
related with the outcome at effective sample sizes greater than 30. However, the
potential precision gains depend on the strength of the assumed correlation between
the baseline covariates and the outcome. For small effective sample sizes, the poten-
tial loss in precision when using an adjusted estimator when the baseline covariates
are uncorrelated with the outcome can be roughly the same size of the precision gain
under an assumption of modest correlation. We demonstrate the use of a simple
simulation setting that may be used by researchers interested in evaluating the use
of an adjusted estimator in a small sample RCT.
Primary Reader: Elizabeth Colantuoni, PhD
Secondary Reader: Michael Rosenblum, PhD
iii
Acknowledgments
I would like to express my gratitude to my thesis advisor Elizabeth Colantuoni,
PhD for her guidance, encouragement and continuous support during my Sc.M study
and thesis research, and thesis reader Michael Rosenblum, PhD for his valuable sug-
gestions and comments during my thesis research. I would like to thank Aaron Mil-
stone, MD for supporting this thesis research and sharing the data from the Treating
Parents to Reduce NICU Transmission of Staphylococcus aureus (TREAT Parents)
trial, funded by NIH/AHRQ [R01HS022872].
I thank my friends and fellow graduate students for their academic and emotional
support and friendship. Finally, I would like to thank my family for the continuous
and unconditional support, encouragement and love they have given me during my





List of Tables vii
List of Figures ix
1 Introduction 1
2 Notation and Definitions 6
2.1 Notation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.2 Time to Event Outcome . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.3 Binary Outcome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
3 Simulation Study 11
3.1 The TREAT Parents Trial . . . . . . . . . . . . . . . . . . . . . . . . 11
3.2 Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
v
CONTENTS
3.3 Simulation study . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
3.3.1 Simulation design . . . . . . . . . . . . . . . . . . . . . . . . . 18
3.3.2 Estimators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
4 Results 23
4.1 Primary Endpoint . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
4.2 Secondary Endpoint . . . . . . . . . . . . . . . . . . . . . . . . . . . 27






3.1 Descriptive statistics for three baseline variables from 150 neonates in
the TREAT Parents trial. Values represent n(%) for birth location and
admitted hospital and mean(sd) for birth weight. . . . . . . . . . . . 13
3.2 Hazard Ratios from the Cox proportional hazards model adjusted for
inborn and outborn status, admitted hospital, and birth weight. . . . 14
4.1 Results of the simulation study assuming no treatment effect. For each
scenario and effective sample size (n), the results summarize 10,000
hypothetical trials. Bias, variance and MSE are computed for the
unadjusted (labeled as “Unadj”) and adjusted (labeled as “Adj”) esti-
mators for the marginal log hazard ratio. The relative MSE compared
the unadjusted to adjusted estimator. . . . . . . . . . . . . . . . . . . 25
4.2 Results of the simulation study assuming a benefit of the treatment.
For each scenario and effective sample size (n), the results summarize
10,000 hypothetical trials. Bias, variance and MSE are computed for
the unadjusted (labeled as “Unadj”) and adjusted (labeled as “Adj”)
estimators for the marginal log hazard ratio. The relative MSE com-
pared the unadjusted to adjusted estimator. . . . . . . . . . . . . . . 26
4.3 Results of the simulation study assuming no treatment effect. For each
scenario and effective sample size (n), the results summarize 10,000
hypothetical trials. Bias, variance and MSE are computed for the un-
adjusted (labeled as “RD”) and adjusted (labeled as “ST” for the stan-
dardization estimator, “DR” for the doubly-robust estimator, “PL” for
the PLEASE) estimators for the marginal risk difference. The relative
MSE compared the unadjusted to adjusted estimator. . . . . . . . . . 31
vii
LIST OF TABLES
4.4 Results of the simulation study assuming a benefit of the treatment.
For each scenario and effective sample size (n), the results summarize
10,000 hypothetical trials. Bias, variance and MSE are computed for
the unadjusted (labeled as “RD”) and adjusted (labeled as “ST” for
the standardization estimator, “DR” for the doubly-robust estimator,
“PL” for the PLEASE) estimators for the marginal risk difference. The
relative MSE compared the unadjusted to adjusted estimator. . . . . 32
viii
List of Figures
3.1 Kaplan-meier survival curve for time to concordant colonization (top)
and time to censoring (bottom) over follow up time in days. . . . . . 15
3.2 Complementary log-log plot of the estimated Kaplan Meier survival
function for time to concordant colonization (top) and time to censor-
ing (bottom) over follow up time in days. . . . . . . . . . . . . . . . . 16
4.1 Relationship between relative MSE and effective sample size by the
degree of correlation between the time to event outcome and baseline




We consider two-arm randomized controlled trials (RCTs) where the goal is to
assess the effectiveness of a treatment relative to a control or placebo condition. The
goal is to estimate the marginal or average treatment effect; e.g. for a linear outcome,
the marginal treatment effect is defined as the difference in the population mean out-
come under treatment and the population mean outcome under placebo. In RCTs,
extensive baseline covariates are collected on each subject prior to randomization of
the treatment assignment, including demographics, medical and treatment history,
current symptoms or diseases, and other quantitative health measurements [1]. Typ-
ically, these baseline covariates are used to describe the study population, can be
compared across treatment arms to quantify chance imbalance in the baseline covari-
ates after randomization [1, 2], and may be incorporated into the estimation of the
marginal treatment effect [2], i.e. baseline covariate adjustment. The key benefit
1
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of baseline covariate adjustment is to exploit chance imbalance in baseline covariates
that are prognostic for the outcome of interest with the goal of improving the precision
of the estimated marginal treatment effect. That is, when adjusting for prognostic
baseline covariates, the standard error for the estimated marginal treatment effect is
smaller than that obtained by the unadjusted estimate of the marginal treatment ef-
fect [2], resulting in a gain of statistical power for a fixed sample size when comparing
the adjusted to unadjusted estimator [3].
Adjusted estimators have been proposed for a variety of outcomes, including out-
comes that follow an exponential family distribution [4,5], time to event outcomes [6,7]
and ordinal outcomes [8]. These proposed adjusted estimators all share the desired
property that, asymptotically (i.e. as the sample size goes to infinity), the estimated
marginal treatment effect based on the adjusted estimator is guaranteed to be as
precise or more precise than the unadjusted estimator. Many of the estimators have
been evaluated, via simulation studies [3, 9], for RCT sample sizes which are gener-
ally accepted as “large” in practice (e.g. regulatory Phase III trials, such as [10],
or non-regulatory trials, such as [11]). These simulation studies demonstrate the
potential gains in precision when adjusting for prognostic baseline covariates. For
instance, using simulation studies based on data from the completed MISTIE phase
II trial for a novel treatment for intraventricular hemorrhage, Colantuoni and Rosen-
blum (2015) [3] generated hypothetical phase III trials, each with sample size of 412,
targeting the marginal difference in the risk of a success, defined as the difference
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between the population proportion of patients with a modified Rankin Scale (mRS)
score of 3 or less under the treatment vs. control arm [3, 11]. The simulation results
showed that the relative efficiency (RE, i.e. the ratio of the variance of the unadjusted
to adjusted estimators) ranged from roughly 1.2 to 1.3 when baseline covariates were
prognostic for the outcomes, as observed in the phase II trial [3]. Note that 1 − 1
RE
translates roughly to the relative reduction in required sample size when using the
adjusted estimator compared to the unadjusted estimator, for a fixed power. There-
fore, the range of relative efficiency translate to a 17 to 23% reduction in required
sample size. In addition, these simulation studies demonstrated the potential loss
of precision that an adjusted estimator may experience when the selected baseline
covariates are uncorrelated with the outcome. For example, in the same simulation
study that uses the MISTIE II trial data, the precision losses ranged from 0.7% to
2.8% comparing the adjusted estimator to the unadjusted estimator [3].
The established asymptotic and practical “large” sample size behavior of the pro-
posed adjusted estimators are essential for researchers planning RCTs with “large”
sample sizes. However, there is little to no guidance on the use of the adjusted es-
timators for researchers designing and conducting “small” RCTs, e.g. single center
non-regulatory trials or small Phase II regulatory trials. The goal of this paper is to
demonstrate the potential limitations of baseline covariate adjustment in RCTs with




We are motivated by an ongoing RCT of parent-neonate dyads within two Johns
Hopkins Hospital affiliated Neonatal Intensive Care Units (NICU), complete details
of the TREAT Parents trial in Section 3.1 [12]. The goal of the trial is to evalu-
ate whether treating, with antibiotics vs. placebo, parent(s)/caregiver(s) who are
colonized with Staphylococcus aureus (Staph aureus) at the time of admission of
their neonate to the NICU reduces the risk of the neonate being colonized with the
parental/caregiver strain of Staph aureus, which we will refer to as concordant colo-
nization. The RCT was designed to have 80% power to detect a 60% reduction in the
hazard of concordant colonization comparing the treated and placebo arms, requiring
a total of 40 concordant colonization events to be observed during the course of the
trial. Recall that this number of required events represents the effective sample size
for the trial and thus this trial would be considered “small”. Thus, we consider RCTs
where the outcome of interest is the time of a defined event where observation is
within a fixed follow-up period. This outcome can be evaluated either as a survival
endpoint, where the marginal treatment effect is defined as the relative hazard of the
event comparing the treatment to placebo arm, or as a binary indicator, where the
marginal treatment effect is defined as the absolute difference in the risk of the event
comparing the treatment to placebo arm.
We consider the baseline covariate adjusted estimator for the marginal hazard
ratio proposed by Lu and Tsiatis (2008) [7] and several baseline covariate adjusted
estimators of the marginal risk difference, see Colantuoni and Rosenblum (2015) [3].
4
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In this paper, we demonstrate, via simulation studies designed using a blinded subset
of data from the ongoing TREAT Parents trial, the potential gains and losses in
precision when using the selected adjusted estimators compared to the unadjusted





Within the two-arm randomized trial of N participants, each participant’s data is
a vector (Wi, Ai, Ti, Yi). For the i
th participant, Wi is a vector of baseline covariates
and Ai is the treatment arm indicator (Ai = 1 for treatment, and Ai = 0 for placebo).
We define two outcomes; a survival outcome Ti = min(T
∗
i
, Ci) which is the minimum
of the time when the event occurs (T ∗
i
) and the censoring time (Ci), and a binary
outcome Yi, where Yi = 1 if T
∗
i
< Ci, and Yi = 0 if T
∗
i
≥ Ci. Throughout, we
assume that W , T and Y are observed for all patients (i.e. no missing values for
the baseline covariates or outcomes) and the treatment is assigned with allocation
1:1 (i.e. each patient has probability 1/2 to receive the treatment). As a result of
the randomization, we assume that A is independent of W . We also assume that the
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censoring time, C, is independent of (T ∗,W ) conditional on the treatment assignment
A.
2.2 Time to Event Outcome
For the time to event outcome, we assume that the proportional hazards model
holds; i.e. λT |A(t|a) = λ(t)exp(βa), where λT |A(t|a) is the conditional hazard of
the event at time t given treatment A = a, for a = 0, 1. We define the marginal
treatment effect as the log hazard ratio β, i.e. the log of the hazard of concordant
colonization comparing the treatment and placebo arms. The unadjusted estimator
for β, βPH is the maximum partial likelihood estimator for the coefficient for the
main term of treatment, from a Cox proportional hazards model that includes only
the main term A. Under the proportional hazards model, then the Wald test for βPH
is asymptotically equivalent to the log-rank test for treatment differences [13].
Using semiparametric theory, Lu and Tsiatis (2008) [7] proposed an estimator for
the marginal log hazard ratio that incorporates baseline covariates and is as precise or
more precise than the maximum partial likelihood estimator, βPH , under no additional
assumptions than described above. They derive estimating equations whose solutions
contain all semiparametric estimators for β, including the maximum partial likelihood
estimator. The baseline covariate information is incorporated into both the estimation
of the underlying cumulative hazard function, via the Breslow estimator, and the
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estimation of the cumulative hazard function of the censoring distribution, via the
treatment-specific Nelson-Aalen estimator.
We note that alternative marginal treatment effect definitions for time to event
outcomes include the difference in the mean restricted survival time [6].
2.3 Binary Outcome
For the binary outcomes, we define the marginal treatment effect as the risk dif-
ference, the difference between the population proportion of neonates concordantly
colonized in 90 days post-randomization in the treatment vs control arm. The unad-
justed estimator for the marginal risk difference is the difference between the observed
proportion of neonates who were concordantly colonized in 90 days in treatment ver-
sus control arm. The unadjusted estimator is consistent and asymptotically normal,
but it ignores information in the baseline covariates W . We consider three adjusted
estimators for the marginal risk difference for evaluating their performance relative
to the unadjusted estimator: the model standardization estimator, doubly robust
weighted least squares (DR-WLS) estimator, and the “precise, locally efficient, aug-
mented, simple estimator” (PLEASE).
The model standardization estimator requires two logistic regression working mod-
els for P (Y = 1|A = a,W ), fitted separately for each treatment assignment, a = 0, 1.
The fits of these two models are then applied to all N participants such that estimated
8
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probabilities of P (Y = 1|A = a,W ) for a = 0, 1 are obtained assuming separately
that all N participants received A = 1 and then all participants received A = 0.
The estimate of the marginal risk in the treatment arm, i.e. P (Y = 1|A = 1) is
obtained by taking the average of the N estimated probabilities. The marginal risk
in the placebo arm is estimated similarly and the marginal risk difference is the dif-
ference in the two estimated treatment arm specific marginal risks. Moore and van
der Laan [14] showed that the model standardization estimator is consistent for the
marginal risk difference even if the logistic regression working models are not cor-
rectly specified. The DR-WLS estimator [15] is similar to the model standardization
estimator; the only difference is the creation of a logistic regression working model
for the treatment assignment, i.e. P (A = 1|W ), also known as the propensity score
model, which is used in the fitting of the logistic regression working models. For the
treatment arm, the P (Y = 1|A = 1,W ) is modeled as a weighted logistic regression
model with weights defined as 1 divided by the predicted values for P (A = 1|W )
from the propensity score model. For the placebo arm, the P (Y = 1|A = 0,W ) is
modeled as a weighted logistic regression model with weights defined as 1 divided by
1 minus the predicted values for P (A = 1|W ) from the propensity score model. After
fitting the weighted logistic regression models, the estimator is implemented in the
same way as the model standardization estimator. The double-robustness property
of the DR-WLS estimator guarantees consistency of this estimator as long as either
the propensity score model or logistic regression working model is correctly specified.
9
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Although both the model standardization and DR-WLS estimators are consistent
for the marginal treatment effect; these estimators are not guaranteed to be as precise
or more precise than the unadjusted estimator, as N goes to infinity. Therefore,
we consider one additional adjusted estimator, the PLEASE, which achieves this
property. The PLEASE is a special case of the general class of estimators proposed
by Rotnitzky et al. [16] and starts by fitting the same weighted logistic regression
working models as used in the DR-WLS estimator. Then, two additional covariates
are computed, one for each treatment arm, that are defined as the difference between
the predicted P (Y = 1|A = a,W ) and the estimated marginal risk, P̂ (Y = 1|A = a).
The propensity score model is then refit including these two additional covariates,
the weighted logistic regression models are refit and the marginal risks per treatment
are computed. These additional covariates that are included in the propensity score
model allow this estimator to achieve the desired asymptotic property.
In our simulation studies, we evaluate all three of the adjusted estimators defined




3.1 The TREAT Parents Trial
The Treating Parents to Reduce Neonatal Transmission of Staphylococcus aureus
(TREAT Parents) Trial is a multicenter randomized, masked, placebo-controlled trial
of neonates receiving care in the Neonatal Intensive Care Unit (NICU) to evaluate the
efficacy of treating parent(s)/caregiver(s) colonized with Staphylococcus aureus (Staph
aureus) with short term intranasal mupirocin and topical chlorhexidine antisepsis to
reduce the transmission of the parental or caregiver strain of Staph aureus to the
neonate. The neonate-parent dyad, the unit of analysis, was randomized into the
treatment arm (intranasal mupirocin and topical antisepsis with chlorhexidine cloths)
or placebo arm (placebo intranasal ointment and placebo cloths for skin antisepsis).
The primary endpoint is time to concordant colonization, i.e. neonatal acquisition of
11
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an Staph aureus strain that is concordant to the parental or caregiver Staph aureus
strain. The observation time was censored either administratively at 90 days after
randomization, when a neonate died or was discharged from the NICU. The key
secondary endpoint is the binary indicator of concordant colonization by 90 days
post randomization.
With the assumed placebo arm concordant colonization rate of 10%, the trial was
designed to achieve 80% power to detect a marginal log hazard ratio of -0.92 (i.e.
a hazard ratio of 0.40 or a 60% reduction in the hazard of concordant colonization)
in the treated arm relative to placebo, requiring 40 total concordant colonizations.
The pre-planned statistical analysis of the primary endpoint included estimation of
the marginal log hazard ratio via the method proposed by Lu and Tsiatis (2008) [7]
with adjustment for three baseline variables collected at the time of NICU admission
that were thought to be correlated with the primary outcome: birth weight in grams,
participating hospital (Johns Hopkins Hospital (JHH) vs. Bayview Medical Center
(BMC)) and an indicator for whether the neonate was born at the participating
hospital (inborn) or transferred from home or another hospital (outborn).
3.2 Data
Blinded data on 150 neonate-parent dyads collected by June 16, 2017 were used
for evaluation. Table 3.1 shows descriptive statistics for the three baseline variables of
12
CHAPTER 3. SIMULATION STUDY
the 150 neonate-parent dyads stratified by the binary concordant colonization status
by 90 days of the study. Among the 150 neonates, 90 percent were inborn (n = 135)
and 93 percent were recruited at the JHH site (n=139). The average birth weight is
2049 grams (standard deviation, sd=978). A total of 25 neonates were concordantly
colonized by 90 days. Neonates who were concordantly colonized by 90 days had,
on average, 175g lower birth weight than those who did not become concordantly
colonized, but the difference between the means was not statistically significant (p-
value = 0.4).
Table 3.1: Descriptive statistics for three baseline variables from 150 neonates in the
TREAT Parents trial. Values represent n(%) for birth location and admitted hospital
and mean(sd) for birth weight.
Baseline Variable Concordant No Concordant All neonates
Colonization Colonization
(n=25) (n=125) (n=150)
Birth Location: Inborn 23 (92) 112 (89.6) 135 (90)
Admitted Hospital: JHH 22 (88) 117 (93.6) 139 (92.7)
Birth Weight (g) 1904 (871) 2079 (999) 2049 (978)
To quantify the correlation between the three baseline covariates and concordant
colonization, we fit a Cox proportional hazards model that included main terms for
each of the three baseline covariates. The estimated coefficient for the main term as-
sumes proportional hazards conditional on the baseline covariates. Table 3.2 displays
the estimated hazard ratios from this model. After conditioning on birth weight and
admitted hospital, we estimate that the hazard of concordant colonization is 35%
13
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lower for inborn compared to outborn neonates (hazard ratio, HR: 0.65, 95% confi-
dence interval, CI: 0.14 to 3.10). After conditioning on inborn and outborn status
and birth weight, we estimate that neonates enrolled at the JHH site have 66% lower
hazard of concordant colonization compared to those enrolled at the BMC site (HR:
0.34, 95% CI: 0.10 to 1.16). We also estimate that a 100 g increase in birth weight
increases the hazard of concordant colonization by 2% after conditioning on admitted
hospital and inborn and outborn status.
Table 3.2: Hazard Ratios from the Cox proportional hazards model adjusted for
inborn and outborn status, admitted hospital, and birth weight.
Baseline Variable Hazard Ratio 95% CI P-value
Inborn vs Outborn 0.65 (0.14, 3.10) 0.59
JHH vs BMC 0.34 (0.10, 1.16) 0.08
Birth Weight (100g) 1.02 (0.97, 1.06) 0.41
Figures 3.1 and 3.2 display the estimated Kaplan-Meier and complementary log-
log survival functions, respectively, for both concordant colonization and censoring
(i.e. NICU discharge or death with administrative censoring at 90 days). The comple-
mentary log-log transformation of the survival curves are approximately linear with
time (on the log scale), which is what would be expected if the underlying distribution
of time to concordant colonization and censoring follow an exponential distribution,
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3.3 Simulation study
We conducted a simulation study, based on the TREAT Parents trial, with the
goal of evaluating the statistical performance of the adjusted estimators described
in Sections 2.2 and 2.3 vs. the corresponding unadjusted estimator for the marginal
treatment effects, i.e. log hazard ratio and risk difference, when the effective sample
size of the RCT is small. We considered RCTs with effective sample sizes, i.e. the
number of neonates who become concordantly colonized by 90 days, ranging from 20
to 100. We considered 3 scenarios which were defined by the degree to which the
three baseline covariates are correlated with concordant colonization. In scenario 1,
we assume that the baseline variables are independent of the outcome. In scenarios 2
and 3, we consider cases where the baseline variables are prognostic for the outcome,
details provided below. In scenario 1, there is potential for efficiency loss for the
adjusted estimators relative to the unadjusted estimator since the baseline variables
are uncorrelated with the outcome, but asymptotically there may be no loss. In
scenarios 2 and 3, there is potential for asymptotic efficiency gain when using the
adjusted estimator relative to the unadjusted estimator, but it is not clear what will
happen at finite sample sizes since the gains may be offset by losses due to added
degrees of freedom in fitting the adjusted estimator. We separately consider the 3
scenarios under no and a benefit of the treatment.
For each scenario, 10,000 hypothetical trials were generated and the bias and
variance of the estimated marginal treatment effects were computed, as well as, the
17
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mean square error (MSE) and relative MSE (i.e. the ratio of unadjusted and adjusted
estimator MSE).
3.3.1 Simulation design
In this section, we describe the data generating distributions for (W,A, T, Y ) for
each of the 3 scenarios and treatment effects, given the expected number of concordant
colonizations n = 20, 30, 40, 60, and 100. W includes (X1, X2, X3) corresponding to
birth weight, participating hospital (JHH vs. BMC) and the indicator for inborn vs.
outborn. For each n, we generate hypothetical trials of size N = n × 6 based on
the blinded data from the TREAT Parents trial where we observed 25 concordant
colonizations in 150 recruited trial participants, i.e. a concordant colonization rate of
1/6.
The hypothetical trials of size N were generated as follows:
1. We took a sample of W of size N , with replacement, from the blinded data
from the TREAT Parents trial. To avoid having a discrete population distribu-
tion of these baseline variables, an independent draw from the discrete uniform
distribution on the range [-3,3] was added to the randomly selected birthweight
(in grams).
2. Treatment was assigned independent of W by taking a draw from a Bernoulli
distribution with probability 0.5 of being assigned to the treatment arm.
3. Motivated by the exploratory analysis of the blinded data from the TREAT
18
CHAPTER 3. SIMULATION STUDY
Parents trial, the time to concordant colonization (T ∗) was set to follow an ex-
ponential distribution with hazard λ = 1/17.32×exp(γA+β1X1+β2X2+β3X3).
The hazard of concordant colonization, λ, was computed for each neonate and
then T ∗ was drawn from the respective exponential distribution. To generate
distributions with no treatment benefit, γ was set to 0. To generate distribu-
tions with a treatment benefit, γ was set to -0.94 and -1.00 in scenarios 2 and 3,
respectively; see note below for how we selected these values. We defined three
scenarios based on the strength of the correlation between T ∗ and W as follows:
(a) For scenario 1, where T ∗ was uncorrelated with W , β1 to β3 were set equal
to 0.
(b) For scenario 2, the correlation between T ∗ andW was set to the correlation
observed in the blinded subset of the TREAT Parents trial, i.e. β1 to β3
were set equal to the estimated coefficients from Table 3.2.
(c) For scenario 3, the correlation between T ∗ and W was assumed to be
stronger than that observed in the blinded subset of the TREAT Parents
trial. Specifically, β1 to β3 were set equal to 1.5 times the estimated coef-
ficients from Table 3.2.
Note: We generated outcome data using a proportional hazards model condi-
tional on both A and W . Therefore, the assumption of proportion hazards for
the marginal treatment effect does not necessarily hold. In our simulation study,
the marginal proportional hazards assumption holds in the following cases: no
19
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treatment effect (regardless of correlation between T ∗ and W ) and benefit of
treatment when T ∗ is uncorrelated with W . We next describe how we selected
the values of γ for the simulation distributions corresponding to benefit of treat-
ment. We did this by trial and error, where for each candidate value of γ we
generated a very large number of simulated participants, administratively cen-
sored them at 90 days, and then fitted the Cox proportional hazards model with
only a main term A; we tried different values of γ until the estimated coefficient
on A was approximately equal to -0.92 (which is the marginal hazard ratio that
the TREAT Parents trial was powered to detect). In simulated trials where the
marginal proportional hazards model may be misspecified, the true value of the
estimand was defined as the probability limit of the estimated coefficient on A
in the marginal proportional hazards model, as sample size goes to infinity; we
approximated this limit by fitting the Cox model to 1,000,000 independently
generated data points with administrative censoring at 90 days.
4. An independent censoring time C was generated, assuming the distribution of
censoring times followed an exponential distribution. The mean of the expo-
nential distribution was calibrated to ensure that the targeted mean number of
concordant colonizations was obtained, and varied by scenario and treatment
effect.
(a) For scenario 1, 2.27 and 3.33 days for no and positive treatment benefit
(b) For scenario 2, 2.17 and 3.23 days for no and positive treatment benefit
20
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(c) For scenario 3, 2.04 and 3.13 days for no and positive treatment benefit
5. Lastly, given the values of T ∗ and C, T and Y were computed.
3.3.2 Estimators
For each hypothetical trial generated in the simulation study, we fit the adjusted
estimators described in Sections 2.2 and 2.3 and the corresponding unadjusted esti-
mators for the marginal treatment effects, i.e. log hazard ratio and risk difference. In
this section, we provide details for implementation of the adjusted estimators.
For the primary endpoint, i.e. time to concordant colonization, the unadjusted
marginal treatment effect is obtained by fitting a Cox proportional hazards model
with a main term A. To obtain the adjusted marginal treatment effect, the method
of Lu and Tsiatis was implemented including main terms for X1, X2, and X3 in both
the linear models for baseline hazards and hazard for the censoring distribution. Note
that in scenario 1, both of these linear models contain the true model; however, in
scenarios 2 and 3, these linear models are not correctly specified.
For the secondary endpoint, i.e. the binary indicator of concordant colonization
by 90 days after randomization, the marginal treatment effect is the risk difference
and the unadjusted estimator is the difference between the proportion of neonates
concordantly colonized in the treatment and placebo arms. Three marginal adjusted
estimators were implemented, and these include the model standardization estimator,
the DR-WLS estimator and PLEASE. All three of the adjusted estimators require
21
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specification of a working outcome regression model; which was defined as a logis-
tic regression model for the binary indicator of concordant colonization by 90 days
and includes main terms for X1, X2, and X3. The DR-WLS estimator and PLEASE
require an additional working model, the propensity score model for treatment as-
signment. We defined the propensity score model as a logistic model for A as a
function of main terms for X1, X2, and X3. The working propensity score model is
correctly specified as the true model, i.e. a logistic model for treatment assignment
that contains only an intercept, is contained within our working model. The working
outcome regression model is not required to be correctly specified in order to obtain
consistent estimates of the marginal treatment effect; the doubly robust properties of
the DR-WLS estimator and PLEASE guarantee consistency of the estimators when




We conducted simulation studies considering effective sample sizes of 20, 30, 40,
60 and 100, thus generating hypothetical trials of size 120, 180, 240, 360, and 600 sub-
jects, respectively. In this section, we provide the results of our simulation studies for
both the time to event outcome (primary endpoint) and binary outcome (secondary
endpoint). For each outcome, we evaluated the performance of the unadjusted and
adjusted estimators by computing the bias, variance, and mean squared error (MSE).
In addition, we computed the relative MSE defined as the MSE of the unadjusted




Table 4.1 summarizes the results of the simulation study when there is no benefit
of the treatment. The bias of both the unadjusted and adjusted estimators is small
for all scenarios and effective sample sizes. As expected, within a scenario (i.e. data
generated under the same assumed correlation between T ∗ and W ), we observe de-
creasing variance with increasing effective sample size. For scenario 1, where T ∗ and
W are uncorrelated, there is a loss of precision for estimating the marginal treatment
effect when using the adjusted estimator compared to the unadjusted estimator. For
instance, the precision loss is roughly 5% for trials with effective sample size of 20.
This precision loss decreases as the effective sample size increases; however, we note
that even at an effective sample size of 60, the precision loss is 2.3%. In scenario 2,
where the correlation between T ∗ and W is the correlation observed in the blinded
subset of the TREAT Parents trial data, we observe a 3 and 1% loss of precision for
effective sample sizes of 20 and 30, respectively, when using the adjusted estimator
compared to the unadjusted estimator. However, for effective sample sizes of 40 and
greater, we observe precision gains on the order of 1 to roughly 2% when using the
adjusted estimator relative to the unadjusted estimator. In scenario 3, where the
correlation between T ∗ and W is increased by 50% compared to what we observed in
the blinded subset of the TREAT Parents trial data, the precision gains are observed
starting at effective sample sizes of 30 and range from 3% to 8%.
Table 4.2 shows the results from the simulation study where we assume a benefit
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Table 4.1: Results of the simulation study assuming no treatment effect. For each
scenario and effective sample size (n), the results summarize 10,000 hypothetical
trials. Bias, variance and MSE are computed for the unadjusted (labeled as “Unadj”)
and adjusted (labeled as “Adj”) estimators for the marginal log hazard ratio. The
relative MSE compared the unadjusted to adjusted estimator.
Bias Variance MSE Relative MSE
Scenario n Unadj Adj Unadj Adj Unadj Adj Unadj/Adj
20 0.0042 0.0048 0.2423 0.2539 0.2423 0.2539 0.954
30 -0.0002 -0.0006 0.1497 0.1549 0.1497 0.1549 0.966
1 40 -0.0007 -0.0016 0.1076 0.1116 0.1076 0.1116 0.964
60 -0.0018 -0.0015 0.0698 0.0715 0.0699 0.0715 0.977
100 -0.0029 -0.0037 0.0405 0.0411 0.0405 0.0411 0.985
20 0.0017 0.0000 0.2370 0.2449 0.2370 0.2449 0.968
30 -0.0008 -0.0013 0.1411 0.1424 0.1411 0.1424 0.991
2 40 -0.0038 -0.0025 0.1089 0.1083 0.1089 0.1083 1.005
60 -0.0070 -0.0074 0.0687 0.0672 0.0687 0.0673 1.021
100 0.0000 0.0001 0.0406 0.0397 0.0406 0.0397 1.023
20 -0.0051 -0.0057 0.2396 0.2416 0.2396 0.2416 0.992
30 -0.0087 -0.0080 0.1481 0.1443 0.1482 0.1444 1.026
3 40 0.0001 -0.0013 0.1099 0.1049 0.1099 0.1049 1.048
60 0.0011 0.0018 0.0712 0.0668 0.0712 0.0668 1.066
100 -0.0019 -0.0024 0.0424 0.0391 0.0424 0.0391 1.084
of the treatment, such that the marginal log hazard ratio is -0.92. For all scenarios, we
observe bias in the estimate of the marginal treatment effect for effective sample sizes
of 20 to 40; with greater bias in the unadjusted compared to the adjusted estimator.
Otherwise, the general patterns we observed for the no treatment effect simulation
setting are replicated when assuming a treatment benefit. If the joint distribution of
(T, Y,W ) in the completed TREAT Parents trial is similar to the distribution we have
assumed in our simulation study, then any gains from adjustment would be negligible
(at 40 concordant colonizations, precision gains of 0.34%).
In the simulation study, we used the speffSurv function, see R package ‘sp-
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Table 4.2: Results of the simulation study assuming a benefit of the treatment. For
each scenario and effective sample size (n), the results summarize 10,000 hypothetical
trials. Bias, variance and MSE are computed for the unadjusted (labeled as “Unadj”)
and adjusted (labeled as “Adj”) estimators for the marginal log hazard ratio. The
relative MSE compared the unadjusted to adjusted estimator.
Bias Variance MSE Relative MSE
Scenario n Unadj Adj Unadj Adj Unadj Adj Unadj/Adj
20 -0.0438 -0.0295 0.2983 0.3175 0.3002 0.3184 0.943
30 -0.0311 -0.0175 0.1843 0.1934 0.1852 0.1937 0.957
1 40 -0.0190 -0.0046 0.1337 0.1372 0.1341 0.1372 0.977
60 -0.0087 0.0043 0.0841 0.0860 0.0842 0.0860 0.979
100 -0.0051 0.0058 0.0490 0.0502 0.0491 0.0502 0.977
20 -0.0491 -0.0340 0.2880 0.3076 0.2905 0.3087 0.941
30 -0.0357 -0.0191 0.1859 0.1909 0.1872 0.1913 0.979
2 40 -0.0250 -0.0069 0.1308 0.1309 0.1314 0.1310 1.003
60 -0.0127 0.0065 0.0833 0.0825 0.0835 0.0825 1.012
100 -0.0072 0.0087 0.0490 0.0479 0.0491 0.0480 1.023
20 -0.0479 -0.0347 0.2899 0.3064 0.2922 0.3076 0.950
30 -0.0312 -0.0144 0.1878 0.1834 0.1888 0.1836 1.028
3 40 -0.0204 -0.0024 0.1300 0.1237 0.1305 0.1237 1.055
60 -0.0154 0.0034 0.0833 0.0782 0.0835 0.0782 1.068
100 -0.0093 0.0083 0.0490 0.0455 0.0491 0.0456 1.078
eff2trial’ [17], to estimate the “adjusted” marginal log hazard ratio, the marginal
log hazard ratio estimated by leveraging prognostic baseline covariates. For small ef-
fective sample sizes, the function sometimes did not find a solution for the “adjusted”
log hazard ratio due to convergence problem; approximately 3 and 24 out of 10,000
hypothetical trials, on average, at an effective sample size of 20 when we assumed no
and a benefit of the treatment, respectively, and 2 hypothetical trials at an effective




We now summarize the simulation results for the secondary outcome, the binary
indicator for concordant colonization within 90 days of randomization. Recall the
marginal treatment effect of interest is the risk difference. Table 4.3 displays the
results from the simulation study assuming that the treatment has no effect. For
all scenarios, the bias is small and similar regardless of the effective sample size. In
scenario 1, where the Y and W are uncorrelated, there are losses in precision for
all the adjusted estimators relative to the unadjusted estimator, as expected. The
loss in precision decreases with increasing effective sample size and we note that the
PLEASE has greater losses in precision compared to the standardization and DR-
WLS estimators. In scenario 2, where the correlation between Y and W is based on
the observed correlation within the blinded subset of the TREAT Parents trial data,
there are precision losses for effective sample sizes 20 and 30. For effective sample
sizes 40 and above, we see a roughly 1 to 2% improvement in precision to estimate
the marginal risk difference comparing the standardization and DR-WLS estimators
to the unadjusted estimators. At effective sample sizes 40 and 60, the PLEASE
demonstrates precision losses, but for effective sample size 100, it demonstrates a
precision gain which is slightly smaller than the precision gains we observe for the
standardization and DR-WLS estimators. When we inflate the observed correlation
between Y and W , in scenario 3, we see precision gains on the order of 1 to 6% for




Table 4.4 displays the results of the simulation study where we assumed a benefit
of the treatment. Here the marginal treatment effect reduces the risk of concordant
colonization within 90 days by 12.5%, absolute risk reduction. Overall, we observed
similar patterns of results compared to when we assumed no treatment effect (see
Table 4.3).
4.3 Illustrative example
In this section, we use the following data generating distributions for (W , A, T , Y )
as another illustrative example to demonstrate the relationship between the number
of events and relative efficiency by varying degrees of correlation between the time to
event endpoint and baseline covariates. We consider only one baseline covariate W
= X1. For each targeted number of events, n = 10, 20, · · · , 80, we generate 10,000
hypothetical trials of size N = n × 6, given the degree of correlation varied from 0
to 0.5 at an increment of 0.1, i.e β = 0, 0.1, 0.2, 0.3, 0.4 and 0.5.
The hypothetical trials of size N are generated in a similar manner as follows: We
generated X1, a random sample of size N from a Normal distribution with mean 0 and
standard deviation 1. Treatment, A, was assigned by taking a draw from a Bernoulli
distribution with probability 0.5 of being assigned to the treatment arm. The time to




shows that the potential precision gains in the estimated treatment effect depend
on the strength of the correlation between the outcome and baseline covariate and
increase with increasing effective sample size. When the outcome and baseline co-
variate are uncorrelated, there is a loss of precision, but this precision loss decreases
as the effective sample size increases. When the outcome and baseline covariate are
correlated, there is no precision gain at an effective sample size of 10; however, for
effective sample sizes of 20 and greater, we start to observe precision gains for the
degrees of correlation of 0.2 and greater. In summary, we observe that the higher the
correlation between the outcome and baseline covariate, the higher the precision gain

















Table 4.3: Results of the simulation study assuming no treatment effect. For each scenario and effective sample size (n),
the results summarize 10,000 hypothetical trials. Bias, variance and MSE are computed for the unadjusted (labeled as
“RD”) and adjusted (labeled as “ST” for the standardization estimator, “DR” for the doubly-robust estimator, “PL”
for the PLEASE) estimators for the marginal risk difference. The relative MSE compared the unadjusted to adjusted
estimator.
Bias Variance MSE Relative MSE
Scenario n RD ST DR PL RD ST DR PL RD ST DR PL RD/ST RD/DR RD/PL
20 0.0007 0.0007 0.0008 0.0009 0.0047 0.0049 0.0049 0.0049 0.0047 0.0049 0.0049 0.0049 0.975 0.974 0.959
30 0.0006 0.0007 0.0007 0.0007 0.0032 0.0032 0.0032 0.0033 0.0032 0.0032 0.0032 0.0033 0.981 0.980 0.965
1 40 0.0004 0.0003 0.0003 0.0003 0.0023 0.0024 0.0024 0.0024 0.0023 0.0024 0.0024 0.0024 0.987 0.987 0.975
60 -0.0002 -0.0002 -0.0002 -0.0002 0.0015 0.0016 0.0016 0.0016 0.0015 0.0016 0.0016 0.0016 0.990 0.989 0.982
100 0.0003 0.0003 0.0003 0.0004 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.994 0.994 0.990
20 0.0035 0.0037 0.0037 0.0037 0.0047 0.0047 0.0047 0.0048 0.0047 0.0047 0.0047 0.0048 0.995 0.994 0.971
30 0.0031 0.0029 0.0029 0.0030 0.0030 0.0030 0.0030 0.0031 0.0030 0.0030 0.0030 0.0031 0.997 0.997 0.979
2 40 0.0019 0.0019 0.0019 0.0020 0.0023 0.0023 0.0023 0.0023 0.0023 0.0023 0.0023 0.0023 1.013 1.012 0.998
60 0.0029 0.0028 0.0028 0.0028 0.0016 0.0015 0.0015 0.0016 0.0016 0.0015 0.0015 0.0016 1.009 1.008 0.999
100 0.0024 0.0024 0.0024 0.0024 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 1.020 1.020 1.016
20 -0.0025 -0.0023 -0.0023 -0.0022 0.0047 0.0046 0.0046 0.0047 0.0047 0.0046 0.0046 0.0047 1.016 1.015 0.990
30 -0.0026 -0.0026 -0.0026 -0.0025 0.0031 0.0030 0.0030 0.0030 0.0031 0.0030 0.0030 0.0031 1.030 1.029 1.008
3 40 -0.0018 -0.0020 -0.0020 -0.0019 0.0024 0.0023 0.0023 0.0023 0.0024 0.0023 0.0023 0.0023 1.047 1.046 1.033
60 -0.0014 -0.0013 -0.0013 -0.0013 0.0016 0.0015 0.0015 0.0015 0.0016 0.0015 0.0015 0.0015 1.049 1.048 1.039

















Table 4.4: Results of the simulation study assuming a benefit of the treatment. For each scenario and effective sample size
(n), the results summarize 10,000 hypothetical trials. Bias, variance and MSE are computed for the unadjusted (labeled
as “RD”) and adjusted (labeled as “ST” for the standardization estimator, “DR” for the doubly-robust estimator, “PL”
for the PLEASE) estimators for the marginal risk difference. The relative MSE compared the unadjusted to adjusted
estimator.
Bias Variance MSE Relative MSE
Scenario n RD ST DR PL RD ST DR PL RD ST DR PL RD/ST RD/DR RD/PL
20 0.0029 0.0030 0.0030 0.0031 0.0046 0.0047 0.0047 0.0048 0.0046 0.0047 0.0047 0.0048 0.969 0.968 0.950
30 0.0020 0.0020 0.0020 0.0019 0.0030 0.0031 0.0031 0.0031 0.0030 0.0031 0.0031 0.0031 0.981 0.981 0.969
1 40 0.0021 0.0020 0.0020 0.0021 0.0023 0.0023 0.0023 0.0024 0.0023 0.0023 0.0023 0.0024 0.986 0.986 0.977
60 0.0019 0.0019 0.0019 0.0019 0.0015 0.0015 0.0015 0.0015 0.0015 0.0015 0.0015 0.0015 0.994 0.993 0.983
100 0.0020 0.0020 0.0020 0.0019 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.997 0.996 0.993
20 -0.0014 -0.0012 -0.0012 -0.0010 0.0045 0.0046 0.0046 0.0047 0.0045 0.0046 0.0046 0.0047 0.982 0.979 0.957
30 -0.0016 -0.0016 -0.0016 -0.0018 0.0031 0.0030 0.0031 0.0031 0.0031 0.0031 0.0031 0.0031 1.002 1.002 0.987
2 40 -0.0019 -0.0019 -0.0019 -0.0018 0.0023 0.0023 0.0023 0.0023 0.0023 0.0023 0.0023 0.0023 1.011 1.011 0.993
60 -0.0005 -0.0005 -0.0005 -0.0005 0.0015 0.0015 0.0015 0.0015 0.0015 0.0015 0.0015 0.0015 1.010 1.009 0.996
100 -0.0010 -0.0010 -0.0010 -0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 0.0009 1.019 1.019 1.015
20 -0.0019 -0.0018 -0.0018 -0.0019 0.0044 0.0044 0.0044 0.0045 0.0044 0.0044 0.0044 0.0045 1.016 1.013 0.983
30 -0.0019 -0.0018 -0.0018 -0.0018 0.0031 0.0030 0.0030 0.0030 0.0031 0.0030 0.0030 0.0031 1.047 1.046 1.028
3 40 -0.0014 -0.0015 -0.0015 -0.0016 0.0022 0.0021 0.0021 0.0022 0.0022 0.0021 0.0021 0.0022 1.051 1.051 1.034
60 -0.0021 -0.0022 -0.0022 -0.0022 0.0015 0.0014 0.0014 0.0014 0.0015 0.0014 0.0014 0.0014 1.054 1.054 1.045




In this work, we have evaluated the performance of several adjusted estimators
of marginal treatment effects within RCTs with small sample sizes. Small sample
size RCTs may include pilot RCTs evaluating feasibility to recruit, retain and treat
patients, Phase II regulatory trials, confirmatory RCTs of expensive interventions or
confirmatory RCTs conducted for rare outcomes. We were motivated by the TREAT
Parents trial, being conducted in two Johns Hopkins Hospital system NICUs, eval-
uating the impact of treating parents colonized with Staph aureus to minimize the
transmission of the parental strain of Staph aureus to the hospitalized neonate. This
study required a total of 40 concordantly colonized neonates to detect the hypothe-
sized benefit of treating the parents with nasal antibiotics and chlorhexidine bathing
compared to placebo (log hazard ratio of -0.92) with 80% power. We evaluated the
potential benefits of using baseline covariate adjustment on the primary (time to con-
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cordant colonization) and secondary (ever concordantly colonized by 90 days post
randomization) endpoints in the TREAT Parents study.
We designed simulation studies that reflected the observed characteristics within
a blinded subset of the TREAT Parents trial data. Based on the targeted effective
sample size for the trial (n = 40) and hypothesized treatment effect, we found that
the adjusted estimators for both the log hazard ratio for the time to event endpoint
and risk difference for the binary endpoint would result in no substantial gain in
precision compared to using the corresponding unadjusted estimators. However, in
cases where the baseline covariates demonstrate greater prognostic ability for the
primary and secondary endpoints (e.g. increased correlation by 50%), we observed
precision gains of roughly 5% at effective sample sizes as small as 30.
For researchers designing RCTs with small effective sample sizes, the decision to
use an adjusted estimator for the marginal treatment effect should be driven by the
degree to which a small number of a priori selected baseline variables are correlated
with the outcome of interest. Our simulation studies demonstrate that for a fixed
effective sample size (e.g. n = 30), the potential precision loss if the baseline variables
are uncorrelated or only weakly correlated with the primary outcome (roughly 2%)
can be roughly the same as the potential precision gain if the baseline variables are
more strongly correlated with the primary outcome. Therefore, researchers planning




If possible, we recommend evaluating whether baseline variables are prognostic
for the outcome of interest using data from observational studies or completed RCTs
of similar patient populations. For the time to event outcome, we summarized the
strength of association using the Cox proportional hazards model. For outcomes that
follow an exponential family distribution, the relative R-square calculation proposed
by Moore and van der Laan [14] may be applied to existing data. Alternatively,
simulation studies, as demonstrated in Chapter 3 and Chapter 4 (see Section 4.3)
may be used to determine if, under the specified assumptions, there is likely a benefit
of using baseline variable adjusted estimators of the marginal treatment effect.
Our work has several limitations that should be addressed moving forward. First,
we have designed our simulation studies using parametric survival models. It would
be useful to consider additional simulation settings with different parametric survival
models or design simulation settings based on resampling data from completed trials
to generate hypothetical trials from unknown data generating distributions. Second,
we explored the performance of the adjusted estimator of Lu and Tsiatis based on
data generating distributions where censoring was independent of treatment and W .
It would be informative to evaluate the performance of this method under violations
of this assumption. Third, there are alternative adjusted estimators that have been
proposed for time to event outcomes, see [6]. Diaz et al propose an adjusted estimator
for the difference in mean restricted survival time to day τ comparing treatment to
placebo arms that, asymptotically, is guaranteed to be as precise or more precise
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than the unadjusted estimator and can account for censoring that may depend on
the treatment assignment or baseline variables. It would be useful to evaluate the
performance of this estimator under small effective sample sizes. Lastly, we used the
coefficients from the Cox proportional hazards model as a way to measure correlation
between the baseline variables and the time to event outcome. It would be useful to
explore the potential for a statistic, similar to the relative R-square cited above, that
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